{"meta":{"query_hash":"24ababab392c","filters":{"venue":"Current Drug Targets - CNS & Neurological Disorders"},"cohort_total":7,"direct_labels_cover":0,"predictions_cover":7,"exported":7,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/24ababab392c","api":"https://metacan.xera.ac/api/v1/cohort?venue=Current+Drug+Targets+-+CNS+%26+Neurological+Disorders"},"results":[{"id":"W1985778670","doi":"10.2174/156800705774322067","title":"Abeta Immunotherapy and Other Means to Remove Amyloid","year":2005,"lang":"en","type":"review","venue":"Current Drug Targets - CNS & Neurological Disorders","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Presenilin; Genetically modified mouse; Alzheimer's disease; Amyloid precursor protein; Transgene; Amyloid (mycology); Immunotherapy; Amyloid beta; Disease; Medicine; Chemistry; Immunology; Immune system; Biochemistry; Pathology","score_opus":0.05743566858691119,"score_gpt":0.3751797894650004,"score_spread":0.31774412087808923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985778670","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042658625,0.9930287,0.000017255043,0.001134473,0.00032628514,0.0032978936,0.00034765253,0.0001917305,0.0012294428],"genre_scores_gemma":[0.00039196594,0.9968982,0.00012550298,0.0012395052,0.00030742053,0.00045607978,0.00029973921,0.00015142078,0.00013019449],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99553674,0.00043017964,0.00075677125,0.0014068953,0.0007131325,0.0011562959],"domain_scores_gemma":[0.99752414,0.00025794652,0.0002244241,0.0008339438,0.000065126136,0.0010944005],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022637619,0.0010420018,0.0022444872,0.00035519863,0.0002141016,0.00007721113,0.000445177,0.0003018655,0.0009264797],"category_scores_gemma":[0.000141441,0.0006928463,0.00092347624,0.00048420095,0.00033129458,0.00008444783,0.0002597606,0.0011441965,0.00063841883],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023682277,0.0014536813,0.00093747466,0.0012395793,0.002327495,0.00006685419,0.000065616565,9.2294425e-7,1.5157215e-7,0.00005322493,0.0036251268,0.98999304],"study_design_scores_gemma":[0.0012982008,0.00061567914,0.00073429174,0.0010178254,0.0014528307,0.000029734718,0.0000072720054,0.000018320101,1.579617e-7,0.00018242643,0.9940816,0.00056162896],"about_ca_topic_score_codex":0.000021340382,"about_ca_topic_score_gemma":0.00001573438,"teacher_disagreement_score":0.9904565,"about_ca_system_score_codex":0.00008117101,"about_ca_system_score_gemma":0.00024329952,"threshold_uncertainty_score":0.9999868},"labels":[],"label_agreement":null},{"id":"W1987897200","doi":"10.2174/1568007053544183","title":"NMDA/NR2B Selective Antagonists in the Treatment of Ischemic Brain Injury","year":2005,"lang":"en","type":"review","venue":"Current Drug Targets - CNS & Neurological Disorders","topic":"Neuroscience and Neuropharmacology Research","field":"Neuroscience","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Ifenprodil; NMDA receptor; Neuroprotection; Glutamate receptor; Neuroscience; Medicine; Pharmacology; Receptor; Neurotransmission; Biology; Internal medicine","score_opus":0.09252142624873262,"score_gpt":0.4242557918291176,"score_spread":0.331734365580385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987897200","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03172891,0.95977426,0.0000016782957,0.002032486,0.0012987629,0.004098876,0.0002987736,0.00012926293,0.0006369986],"genre_scores_gemma":[0.013960395,0.983643,0.000002172916,0.0011816053,0.00019384264,0.00078822504,0.00001946415,0.00006760839,0.00014369229],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99104977,0.0033696843,0.0011270678,0.0021093052,0.00089600263,0.0014482024],"domain_scores_gemma":[0.9951393,0.0032358938,0.0005584544,0.00080036203,0.000038029833,0.00022796803],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004857919,0.0010314246,0.0019015957,0.0005928872,0.00036965392,0.00008585385,0.0023438327,0.00028993242,0.00012807979],"category_scores_gemma":[0.00090870366,0.00062199583,0.0009186868,0.002342223,0.0014739566,0.0002170534,0.0002953999,0.0019722916,0.00013784794],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016462863,0.0049734456,0.0001569651,0.00069964805,0.000014610282,0.00012714729,0.0003945706,0.000008443203,0.0014003054,0.000068559704,0.011305447,0.98068625],"study_design_scores_gemma":[0.00057743525,0.0014757632,0.00006583672,0.00014053838,0.00010626427,0.00003410497,0.000008416461,0.000050224317,0.00079932174,0.00008689722,0.9961635,0.0004917144],"about_ca_topic_score_codex":0.0000070130177,"about_ca_topic_score_gemma":0.000011755682,"teacher_disagreement_score":0.98485804,"about_ca_system_score_codex":0.00010499559,"about_ca_system_score_gemma":0.00035700985,"threshold_uncertainty_score":0.9996231},"labels":[],"label_agreement":null},{"id":"W2005425566","doi":"10.2174/156800705774322085","title":"Cholesterol and Apoe: A Target for Alzheimers Disease Therapeutics","year":2005,"lang":"en","type":"review","venue":"Current Drug Targets - CNS & Neurological Disorders","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Pathogenesis; Disease; Apolipoprotein E; Alzheimer's disease; Medicine; Cholesterol; Apolipoprotein B; Bioinformatics; Immunology; Internal medicine; Biology","score_opus":0.0708535222575065,"score_gpt":0.36555977612965285,"score_spread":0.29470625387214633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005425566","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018240174,0.9901867,0.0003523927,0.0016652031,0.0007802644,0.006227213,0.00031941946,0.00019378729,0.000092606024],"genre_scores_gemma":[0.00044827088,0.9946439,0.00027621587,0.0013592126,0.0008523142,0.0013728909,0.0008288443,0.00015349568,0.00006480492],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99565107,0.00039870007,0.0008937321,0.0014225111,0.00061649433,0.00101752],"domain_scores_gemma":[0.9975373,0.00020234236,0.00034144154,0.000940348,0.000082126884,0.00089644326],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005025479,0.0010176013,0.0026832605,0.00021440451,0.000263823,0.000069829046,0.00035794746,0.0003682233,0.00007956435],"category_scores_gemma":[0.00015242313,0.00070629286,0.002023655,0.000289147,0.00032366722,0.00009456018,0.00019330886,0.0012289921,0.000034847857],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011403079,0.00055510626,0.00010759311,0.008288805,0.0005072811,0.000009228569,0.000029599745,0.0000032232153,2.5741196e-8,0.000074278505,0.0013257621,0.98898506],"study_design_scores_gemma":[0.0015744772,0.00042524087,0.00055911334,0.001082692,0.0049502067,0.00002350451,0.000006402131,0.00016764706,6.613209e-8,0.00023450966,0.99034387,0.0006322993],"about_ca_topic_score_codex":0.0000044130425,"about_ca_topic_score_gemma":0.000003968717,"teacher_disagreement_score":0.9890181,"about_ca_system_score_codex":0.00004992681,"about_ca_system_score_gemma":0.00036790402,"threshold_uncertainty_score":0.99953884},"labels":[],"label_agreement":null},{"id":"W2056349137","doi":"10.2174/1568007043337076","title":"Exercise in a Pill: Feasibility of Energy Expenditure Targets","year":2004,"lang":"en","type":"review","venue":"Current Drug Targets - CNS & Neurological Disorders","topic":"Energy, Environment, and Transportation Policies","field":"Energy","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Pill; Energy expenditure; Energy metabolism; Medicine; Pharmacology; Internal medicine","score_opus":0.035012071385641434,"score_gpt":0.3033825570588669,"score_spread":0.26837048567322547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056349137","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006878824,0.99577814,0.000067105466,0.00010035008,0.0010187095,0.00080779043,0.00026036546,0.00017564966,0.0011039982],"genre_scores_gemma":[0.024255892,0.9732352,0.0000519055,0.000081721366,0.00008658247,0.00050451513,0.0015386222,0.00012725059,0.000118309414],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99425745,0.0005409899,0.0018860978,0.0015835158,0.00066013914,0.0010717986],"domain_scores_gemma":[0.99749684,0.00025484123,0.0008676632,0.0010124742,0.000031799806,0.00033635518],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002499037,0.001269355,0.0029945942,0.00048344117,0.00013136269,0.000029132916,0.0010218538,0.0006475057,0.00074648415],"category_scores_gemma":[0.00010746206,0.0010174342,0.001349627,0.00063878385,0.00059714133,0.00018665356,0.00017192155,0.0011302094,0.000035188732],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020117602,0.0063522756,0.0020227048,0.017998664,0.00020839625,0.00010581145,0.00076267,0.011512535,0.0000020659031,0.02979019,0.0010899971,0.9299535],"study_design_scores_gemma":[0.00092563103,0.000116656774,0.0018227963,0.002630354,0.00036176332,0.0000023931589,0.000023588218,0.000016039608,0.0000041139397,0.008860978,0.9842913,0.0009443974],"about_ca_topic_score_codex":0.00066275924,"about_ca_topic_score_gemma":0.0011552859,"teacher_disagreement_score":0.98320127,"about_ca_system_score_codex":0.00013122581,"about_ca_system_score_gemma":0.00017186221,"threshold_uncertainty_score":0.9992276},"labels":[],"label_agreement":null},{"id":"W2065097064","doi":"10.2174/1568007033338832","title":"Osteoporosis in Anorexia Nervosa: A Brittle Future","year":2003,"lang":"en","type":"review","venue":"Current Drug Targets - CNS & Neurological Disorders","topic":"Eating Disorders and Behaviors","field":"Psychology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Anorexia nervosa; Osteopenia; Osteoporosis; Medicine; Anorexia; Pediatrics; Endocrinology; Internal medicine; Eating disorders; Psychiatry; Bone mineral","score_opus":0.04091482381570872,"score_gpt":0.3522683560232328,"score_spread":0.3113535322075241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065097064","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020673627,0.9850322,0.000006252911,0.00023875252,0.006847963,0.0020178927,0.00015671599,0.00026143872,0.0033714278],"genre_scores_gemma":[0.0002800923,0.9963837,0.000053860644,0.000351604,0.0003626489,0.0010082938,0.0007297642,0.00018417077,0.0006458397],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924529,0.0015505885,0.0015740067,0.0022410795,0.0005052299,0.0016761628],"domain_scores_gemma":[0.9974229,0.00032401187,0.00069597637,0.0011483857,0.000052025516,0.0003567482],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0004324827,0.0014847758,0.0029280628,0.00054279505,0.00024411801,0.00010221606,0.0012399112,0.0010711539,0.00378295],"category_scores_gemma":[0.00009895239,0.001183874,0.0014487809,0.0014464254,0.00038258554,0.000115868126,0.00027925763,0.003067511,0.00075960736],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028028544,0.002692663,0.011580335,0.0014604455,0.00005617394,0.000084089705,0.00041792612,0.0000021061298,4.5592415e-8,0.0003583838,0.039379675,0.9439401],"study_design_scores_gemma":[0.00081970886,0.00033064076,0.0025264926,0.00060665724,0.00046360065,0.000022938335,0.00017380806,0.000002209582,4.4443893e-9,0.0005329434,0.9933353,0.001185695],"about_ca_topic_score_codex":0.00009199131,"about_ca_topic_score_gemma":0.00026554507,"teacher_disagreement_score":0.95395565,"about_ca_system_score_codex":0.000069844136,"about_ca_system_score_gemma":0.00014410216,"threshold_uncertainty_score":0.99979013},"labels":[],"label_agreement":null},{"id":"W2072477505","doi":"10.2174/156800705774322058","title":"CREB, Synapses and Memory Disorders: Past Progress and Future Challenges","year":2005,"lang":"en","type":"review","venue":"Current Drug Targets - CNS & Neurological Disorders","topic":"Phosphodiesterase function and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":186,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; SickKids Foundation","funders":"","keywords":"CREB; Neuronal memory allocation; Neuroscience; Long-term potentiation; Aplysia; Synaptic plasticity; Transcription factor; Biology; Neuroplasticity; Cell biology; Metaplasticity; Gene; Genetics; Receptor","score_opus":0.021891309593915415,"score_gpt":0.29220355067183246,"score_spread":0.27031224107791707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072477505","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014643677,0.9940754,0.000011397237,0.0021721958,0.0010307283,0.0009121101,0.0000586307,0.000069478745,0.00020565973],"genre_scores_gemma":[0.001324779,0.99634814,0.000035257228,0.0001209886,0.0011946381,0.00021981884,0.00061503047,0.00005826277,0.000083076004],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99734366,0.00032577035,0.00046218364,0.0011876568,0.00019748489,0.0004832342],"domain_scores_gemma":[0.9990142,0.00005295574,0.0002777754,0.00039556273,0.00003630912,0.00022317338],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015054799,0.00072750926,0.00089487655,0.00010828538,0.0002253683,0.000065902816,0.00025355304,0.00051603594,0.000037814418],"category_scores_gemma":[0.000042474385,0.00052466366,0.00031379197,0.00011021206,0.0005132327,0.000015388416,0.00034816717,0.0005059998,0.000006203861],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004175906,0.00024947472,0.00015825662,0.0016678555,0.000077592624,0.0000017130742,0.000050746115,0.000001297501,6.671118e-7,0.000059479313,0.0017524466,0.9959387],"study_design_scores_gemma":[0.00038749666,0.00029499282,0.0010143559,0.0002467938,0.00021601762,0.000020835776,0.00005057573,0.000012628561,6.782988e-7,0.00010555205,0.99707305,0.0005770274],"about_ca_topic_score_codex":9.31473e-7,"about_ca_topic_score_gemma":0.000037647755,"teacher_disagreement_score":0.9953617,"about_ca_system_score_codex":0.000008534699,"about_ca_system_score_gemma":0.000045237597,"threshold_uncertainty_score":0.9997205},"labels":[],"label_agreement":null},{"id":"W2112341182","doi":"10.2174/1568007023338914","title":"Galanin: A Biologically Active Peptide","year":2002,"lang":"en","type":"review","venue":"Current Drug Targets - CNS & Neurological Disorders","topic":"Neuropeptides and Animal Physiology","field":"Neuroscience","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Galanin; Galanin receptor; Neuropeptide; Internal medicine; Endocrinology; Biology; Central nervous system; Receptor; Medicine","score_opus":0.08688973407603384,"score_gpt":0.3283329591641141,"score_spread":0.24144322508808025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112341182","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009938393,0.98731506,0.000006421794,0.0001987414,0.0018821615,0.0020505479,0.00044505918,0.00071268465,0.0063954783],"genre_scores_gemma":[0.0025071164,0.99471045,0.000018547935,0.0011763816,0.00045200088,0.00037151226,0.00014250954,0.00015141164,0.00047007366],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9912963,0.001816614,0.0012995593,0.00322959,0.0005594894,0.0017984839],"domain_scores_gemma":[0.99600756,0.0016053071,0.0008928974,0.0009211348,0.00005057623,0.0005225333],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.00014779759,0.0016882305,0.0030933528,0.00031277403,0.0004977173,0.00013832553,0.0022582728,0.00053353305,0.001623596],"category_scores_gemma":[0.0013039426,0.0011267955,0.0018384047,0.00096651824,0.0010507166,0.00022127733,0.0011911929,0.0031114572,0.003004911],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007673811,0.0011879138,0.000016079472,0.0015536066,0.000029855955,0.00016874877,0.00003461608,0.0000049187793,0.00017589361,0.0010423935,0.010130548,0.9855787],"study_design_scores_gemma":[0.00031049366,0.00079376483,0.000086166445,0.00059808424,0.0002052801,0.000053135314,0.00000364137,0.00003566603,0.000008839198,0.0016204559,0.9951175,0.0011670017],"about_ca_topic_score_codex":0.0000034858851,"about_ca_topic_score_gemma":0.0000026172609,"teacher_disagreement_score":0.9849869,"about_ca_system_score_codex":0.000051464587,"about_ca_system_score_gemma":0.000086563356,"threshold_uncertainty_score":0.99958646},"labels":[],"label_agreement":null}]}